Gold prices cool after hitting over 2-week high on Fed independence fears
Investing.com - Cantor Fitzgerald upgraded Supernus Pharmaceuticals (NASDAQ:SUPN) from Neutral to Overweight on Wednesday, while raising its price target to $42.00 from $36.00. According to InvestingPro data, the company maintains a "GREAT" financial health score, with analyst targets ranging from $36 to $45.
The upgrade reflects Cantor Fitzgerald’s increased sales outlook for Qelbree, Supernus Pharmaceuticals’ non-stimulant medication for attention-deficit hyperactivity disorder (ADHD).
The research firm cited its "more positive outlook on Qelbree" as a key factor in the rating change, along with other minor adjustments across its income statement projections for the company.
Cantor Fitzgerald noted the new price target represents significant upside potential compared to Supernus Pharmaceuticals’ current trading price.
The $42.00 price target represents a $6.00 increase from the firm’s previous target of $36.00 for the biopharmaceutical company, which specializes in central nervous system disorders.
In other recent news, Supernus Pharmaceuticals reported its first-quarter 2025 earnings, revealing a net loss that missed analyst expectations. The company posted a GAAP net loss per share of $0.21, while analysts had anticipated earnings of $0.37 per share. However, Supernus’s revenue slightly exceeded forecasts, coming in at $149.8 million compared to the expected $146.9 million. In a significant development, Supernus is moving forward with its acquisition of Sage Therapeutics, having cleared a key regulatory hurdle with the expiration of the Hart-Scott-Rodino Antitrust Improvements Act waiting period.
The acquisition is valued at approximately $561 million in cash, with a potential increase to $795 million based on contingent value rights. Piper Sandler maintained its Neutral rating on Supernus, describing the acquisition as puzzling but acknowledging its potential to diversify the company. Cantor Fitzgerald also reiterated its Neutral rating, highlighting the acquisition’s provision of access to ZURZUVAE, an FDA-approved treatment for postpartum depression. These developments reflect Supernus’s strategic moves to expand its portfolio and address broader market opportunities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.